Page 1682 - Clinical Small Animal Internal Medicine

1620 Index

methicillin‐resistant (MR) anatomy and physiology molecular diagnostics
VetBooks.ir methylxanthine bronchodilators 301 detrusor atony 1186 bacterial infections 844–845
1181, 1182
actinomycosis 978
staphylococci 1059, 1467–1468
fungal infections 846–847
detrusor hyperreflexia/overactive
metronomic chemotherapy
approach to the cancer bladder 1186 mycobacteriosis 982
patient 1203 detrusor urethral dyssynergy nocardiosis 979
biology of cancer and cancer 1186–1187 protozoal and arthropod‐borne
genetics 1209 dysautonomia 1188 infections 843
cardiac neoplasia 1274 emptying disorders 1186–1188 viral infections 844
hemangiosarcoma 1344 lower motor neuron bladder see also genetics and genetic testing;
male reproductive system 1184–1186 individual techniques
tumors 1312 neurogenic functional urethral monoclonal gammopathy of
soft tissue sarcomas 1336–1337 obstruction 1187 unknown significance
MG see myesthenia gravis storage disorders 1181–1186 (MGUS) 1244–1245
MGCS see Modified Glasgow urethral sphincter mechanism monoclonal theory 50–51
Coma Scale incompetence 1182–1184, 1184, Monro–Kellie hypothesis 749–750
MGUS see monoclonal gammopathy of 1185 morulae 909–910
unknown significance migrating motor complex motilin‐like drugs 575, 579
MH see malignant hyperthermia (MMC) 565 motility disorders 563–581
MHC see major histocompatibility mineralocorticoids 86 associated diseases 570–572, 576
complex; myosin heavy chain minichromosome maintenance‐7 causes 563–564, 567
MI see mitotic index (MCM‐7) 51 clinical signs 563, 565–567, 570,
MIC see minimum inhibitory minimum dermatology database 1438 574–576
concentration minimum inhibitory concentration diagnostic tests 564–569, 566, 568,
microarray‐based technology, biology (MIC) 845, 1192 572–574, 573, 576–577
of cancer and cancer genetics Minnesota Urolith Center dysautonomia and other
1207 (MUC) 1127–1132 neuromuscular diseases 570
Microbial Threats to Health: mirror‐image artifacts 663, 663 esophagus 563–565
Emergence, Detection, and mites see individual diseases intestinal pseudoobstruction 571
Response (IoM) 3 mitotic index (MI) 7–8 large intestine 574–579
microcirculation 405 mitral valve insufficiency physiology 563, 565, 569, 574
microhepatica 661, 662 246, 251, 305 postoperative ileus and short bowel
micrometastatic disease mitral valve regurgitation 147–148, syndrome 570–571
1329, 1331 159, 246 prokinetics 574, 575, 579–580
microscopic agglutination test mitral valve stenosis (MVS) 234, 237 secondary small intestinal
(MAT) 946–948 mixed/compound uroliths hypomobility 571–572
microscopic examination see cytology; 1143–1144 small intestine 569–574
histology/histopathology mixed venous oxygen saturation stomach 565–569
microspora 1026 411–412 treatment 565, 569, 574, 575,
microvascular dysplasia MLO see multilobular 577–579, 578
(MVD) 713–720 osteochondrosarcoma mousses 1398
classification and anatomy MM see multiple myeloma movement disorders 766–771
713–714 MMC see migrating motor complex diagnosis 770–771
diagnosis 716 MMM see masticatory muscle myositis etiology/pathophysiology 766–770
etiology 713 MMP see matrix metalloproteinases; fasciculations and myokimia 769
history and clinical signs 716 mucous membrane pemphigoid history 766
hypoglycemia 105 MMVD see myxomatous mitral valve hyperkinetic movement
pathophysiology 714–715, 714 disease disorders 768–769, 768, 771
portal hypertension 715 mobility 352, 1560, 1560 treatment 771
prognosis 719–720 Modified Glasgow Coma Scale tremor syndromes 769–770
signalment 715 (MGCS) 455, 456, 751–752, MPN see myeloproliferative neoplasms
therapeutic decision making 719 752, 758 MR see methicillin‐resistant
treatment 717–720 modified live vaccines 1569 MRI see magnetic resonance imaging
micturition and associated MODS see multiple organ dysfunction MUC see Minnesota Urolith Center
disorders 1181–1188 syndrome mucoceles 721, 722, 724